These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32812020)

  • 1. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation.
    Sugimoto K; Fujita S; Miyazu T; Ishida N; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Furuta T; Osawa S
    Inflamm Bowel Dis; 2021 Jan; 27(1):e3-e4. PubMed ID: 32812020
    [No Abstract]   [Full Text] [Related]  

  • 2. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
    Kupczyk M; Kuna P
    Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benralizumab in Real Life.
    Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
    [No Abstract]   [Full Text] [Related]  

  • 4. Compassionate Use of a Single Dose of Benralizumab in a Near-Fatal Asthma Exacerbation.
    Pérez de Llano L; Blanco Cid N; Ortiz Piquer M; Dacal Rivas D
    J Investig Allergol Clin Immunol; 2021 Jun; 31(3):268-270. PubMed ID: 32938574
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia.
    Isomoto K; Baba T; Sekine A; Aiko N; Ogura T
    Intern Med; 2020 May; 59(9):1195-1198. PubMed ID: 32009090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach.
    Ramakrishnan S; Camp JR; Vijayakumar B; Hardinge FM; Downs ML; Russell REK; Pavord ID; Bafadhel M
    Am J Respir Crit Care Med; 2020 Jun; 201(11):1441-1443. PubMed ID: 32023077
    [No Abstract]   [Full Text] [Related]  

  • 8. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
    Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
    Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma.
    Lommatzsch M; Marchewski H; Schwefel G; Stoll P; Virchow JC; Bratke K
    Clin Exp Allergy; 2020 Nov; 50(11):1267-1269. PubMed ID: 32762056
    [No Abstract]   [Full Text] [Related]  

  • 12. Benralizumab for the treatment of asthma.
    Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
    Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.
    Moran AM; Ramakrishnan S; Borg CA; Connolly CM; Couillard S; Mwasuku CM; Pavord ID; Hinks TSC; Lehtimӓki L
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1314-1316. PubMed ID: 32584603
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
    Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
    J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of whole blood gene expressions correlated with responsiveness to benralizumab.
    Nakajima M; Matsuyama M; Arai N; Yamada H; Hyodo K; Nonaka M; Kitazawa H; Yoshida K; Shigemasa R; Morishima Y; Kiwamoto T; Masuko H; Ishii Y; Muratani M; Saito T; Hizawa N
    J Allergy Clin Immunol; 2021 Feb; 147(2):772-775. PubMed ID: 32795588
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab: an updated treatment of eosinophilic asthma.
    Cushen B; Menzies-Gow A
    Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
    Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
    Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.